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A B S T R A C T
Background
Unit-dose packaging of antimalarial drugs may improve the success of malaria treatments by making it easier for patients to take them
correctly.
Objectives
To summarize the effects of unit-dose packaged treatment on treatment failure and treatment adherence in people with uncomplicated
malaria.
Search strategy
We searched the Cochrane Infectious Diseases Group Specialized Register (February 2009); CENTRAL (The Cochrane Library Issue 1,
2009); MEDLINE (1966 to February 2009); EMBASE (1980 to February 2009); LILACS (February 2009); conference proceedings,
and reference lists of articles. We also contacted pharmaceutical companies, organizations, and researchers in the field.
Selection criteria
Randomized controlled trials (RCTs), cluster-RCTs and quasi-RCTs of unit-dose packaged drugs for treating uncomplicated malaria.
Data collection and analysis
We independently assessed trial eligibility and risk of bias, and extracted data for an intention-to-treat analysis, where possible. We
combined binary data using risk ratio (RR) and the fixed-effect model, and presented them with 95% confidence intervals (CI). We
attempted to contact trial authors for additional information.
Main results
One RCT (203 participants), three quasi-RCTs (895 participants), and one cluster-RCT (six health facilities) met the inclusion criteria.
Trials were generally of poor methodological quality, and none adequately assessed treatment failure. Unit-dose packaged drugs (in
conjunction with prescriber training and patient information) appeared to be associated with higher participant-reported treatment
adherence in all trials.
A meta-analysis of two trials (596 participants) showed that participant-reported treatment adherence was slightly higher with blister-
packed tablets compared with tablets in paper envelopes (RR 1.18, 95%CI 1.12 to 1.25). Two trials using tablets in sectioned polythene
bags as the intervention also noted an increase in participant-reported treatment adherence: the cluster-RCT (six clusters) compared it
with tablets in paper envelopes, and the other trial compared it with syrup in bottles (RR 2.15, 95% CI 1.76 to 2.61; 299 participants).
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Authors’ conclusions
There is insufficient evidence to know if the effects of unit-dose packaged antimalarial drugs reduce treatment failure. Unit-dose
packaging, supported by prescriber training and patient information, appears to improve participant-reported treatment adherence,
but these data come from trials with methodological limitations.
P L A I N L A N G U A G E S U M M A R Y
Unit-dose packaging of drugs for treating malaria
Malaria is a parasitic disease spread by mosquitoes in areas such as sub-Saharan Africa, South-East Asia and South America. Millions
of people are infected with malaria each year. It is thought that packaging a course of treatment in units of a single dose may better
ensure the correct dosage is taken, thus increasing the success of treatment. The review found insufficient good quality evidence from
randomized controlled trials to determine if unit-dose packaging of drugs saves lives, but there is some indication that it might improve
treatment adherence. More research is needed.
B A C K G R O U N D
Treating malaria
Malaria is caused by the Plasmodium parasite, which is spread by
mosquitoes mainly in Africa, Asia, and South America. Millions
of people are infected with malaria each year and many will die (
WHO2004). TheWorldHealthOrganization (WHO) promotes
rapid diagnosis and prompt treatment of malaria to reduce the
burden of the disease (WHO 1993). There is a challenge in ensur-
ing that people are receiving effective drugs to treat malaria. Once
these drugs are available, interventions that aid people in taking
the correct treatment regimen will help maximize their effective-
ness. Suboptimal dosing results in low blood concentrations and
inadequate exposure of the infecting parasite population to ther-
apeutic concentrations of the drug (White 1998; Bloland 2003).
This contributes to fewer cures and parasite recrudescence, and
can contribute to the development of parasite resistance to anti-
malarial drugs.
Some antimalarial drugs, such as sulfadoxine-pyrimethamine and
mefloquine, require only a single dose, making the regimen
straightforward. In fact, as many people attend health facilities for
illness, health staff can directly supervise the dosing of these drugs.
Regimens for other drugs, such as chloroquine and amodiaquine,
span three days. If the drugs are acquired from a health facility the
first dose can be ensured in a similar way, but subsequent doses
may be missed as people usually take these at home. Children
commonly receive bottles of chloroquine syrup for the treatment
of malaria; adequate treatment would require caregivers to use ap-
propriately sized dosing instruments, but this cannot always be
ensured. Newly introduced courses of antimalarial treatment are
increasingly complex. TheWHO currently promotes artemisinin-
based combination therapy (ACT) and, unless the drugs are co-
formulated, this often requires people to follow the regimen for
more than one antimalarial drug at a time. These regimens may
be more difficult to follow correctly.
Understanding adherence
The ability of people to follow a given treatment regimen has been
studied for some time. ’Compliance’, ’concordance’, and ’adher-
ence’ have all been used to describe the concept. Recently, some
experts have discouraged the use of the term ’compliance’ as it may
imply that “the patient is docile and subservient to the provider”
(Sumartojo 1993). Mullen and colleagues suggest ’concordance’
may be more suitable as it reflects “the active exchange of informa-
tion, negotiation, and spirit of cooperation” between patient and
health provider (Mullen 1997). However, it is not widely used.
Haynes and colleagues believe that completing treatment is usu-
ally an independent choice of the patient and is best described as
’adherence’, a statement of fact rather than of blame of the pa-
tient, prescriber, or treatment (Haynes 2008). We use ’adherence’
throughout this review.
Levels of adherence vary widely between treatments for all dis-
ease states (Sackett 1979). Recorded reasons for non-adherence in-
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clude adverse events, poor instructions, poor provider-patient re-
lationship, loss of drugs, forgetting to take treatment, patient’s dis-
agreement with the need for treatment, perceived ineffectiveness
of the drug, and the inability to pay for it (Gomes 1998; Haynes
2008). People are less likely to take medicines once they feel they
have recovered from an illness (White 1998). Most interventions
to promote adherence are targeted at modifying the behaviour of
the patient, caregiver, or health staff (Volmink 1997). Strategies
include education and information campaigns, directly observed
therapy, increased supervision of staff, home visits with follow up,
and improved packaging of drugs.
Drug packaging
In a Cochrane Review, Haynes 2008 summarized the evidence
around interventions used to help patients follow prescriptions for
medications. Three trials included in the review looked at inter-
ventionswith a drug-packaging component. These trials generated
conflicting results. Henry 1999 found that a package of “compli-
ance enhancing measures” did not improve adherence or clinical
outcome for Helicobacter pylori treatment; in fact, adherence and
treatment success were high in both the control and treatment
groups. Similarly, Becker 1986 did not find any improvement
in adherence or blood pressure control for hypertensive patients
receiving special medication packaging. However, Peterson 1984
found that adherence and clinical control improved significantly
in participants given a combination of “compliance-improving
strategies” for the treatment of epilepsy. Another Cochrane Review
Heneghan 2006 has examined reminder packaging as an interven-
tion for improving adherence to self-administered long-termmed-
ications. Eight studies were included in this review. Results were
inconclusive. Whilst the intervetion appeared to improve dosing
and showed the possibility for an effect on adherence, no clinical
benefits of the intervention was demonstarted. The current review
looks at unit-dose drug packaging as an adherence intervention
for malaria treatment.
Historically, drugs were first packaged to preserve freshness, pre-
vent contamination, and protect them from damage (Richardson
2003). It is also an effective way to make them more recogniz-
able, help ensure expired drugs are not used, and prevent under
or over weighing and counterfeiting. Over time, marketers real-
ized the potential of packaging to aid brand advertising. More re-
cently, the design of packaging has been considered a useful tool
to enhance adherence to treatment. Packaging can be designed to
enhance communication of the regimen to patients and providers.
With the aid of improved packaging, providers should be better
able to give the correct amount of the drug, inform patients of
the treatment regimen, and highlight the need for full therapy;
and patients should be better able to use the packaging to guide
treatment, even when unsupervised.
Some drugs have a narrow therapeutic range andmust be packaged
individually for each age or weight category in order to avoid
under or over dosing (Ondari 2003). Labelling of packs can be
problematic as age estimations of mothers have frequently been
found to be unreliable, and many rural villages have no weighing
devices. The use of diagrams (for example, a crawling, walking
or talking child used by Okonkwo 2001) may be an appropriate
alternative in some settings. When drugs are packaged differently,
the entire range must be made available. If not, there is the risk
that people may try to alter the dose by doubling (using two packs)
or halving the packs they can find. This adds a new potential
for miscalculations and under dosing (Kilian 2003). Even when
all presentations are available there is the possibility of over or
under dosing at the extremes of the age range, especially among
populations where malnutrition exists (Bloland 2003).
The system of packaging adopted by each country and each phar-
maceutical company varies widely. This is often due to the dif-
ferent and changing drug policies, various perceptions, the public
and private sector involvement in drug and packaging production,
and the level of technology available. Most packaging develop-
ments have been designed for use with tablets, despite children
traditionally receiving syrup to treat malaria (it is considered eas-
ier to tolerate). Some investigators have developed special syrup
bottles, but tablets are more readily packaged. In particular, blister
packaging of tablets is becoming increasingly popular, especially
with the spread of combination therapy (the two drugs can be
packaged together in one blister (White 1999)). In fact, theWHO
now suggests that all artemisinin-based combination treatments
should be blister packed to conform to good manufacturing prac-
tice standards (WHO 2003). Blister packaging requires a certain
level of technology and, even within this packaging type, there is
great variation in the products developed. For the purpose of this
review, we have extracted as much descriptive information relating
to each packaging intervention as possible and attempted to relate
this to any heterogeneity in the effectiveness of interventions.
Designs that ensure suitability for illiterate or semi-literate carers
through the use of colour coding, pictures, and diagrams, as well
as written instructions, should help optimize the effectiveness of
interventions. One way to improve the suitability of the interven-
tions is to consult with consumer groups at the design stage. In-
formation from health workers often has to compete with other
advice and perceptions before patients decide what to do about
recommended treatments. When designing drug packaging, an
understanding of the user group will help counteract any negative
perspectives, reinforce positive ones, fill in missing information,
answer questions, and overcome suspicion (Francis 1997). Many
episodes of uncomplicated malaria are treated in the home after
initiation at the health centre or entirely through self-treatment (
Biritwum 2000; Kilian 2003). People will often use drugs left over
from a previous episode or will purchase them from private ven-
dors (Biritwum 2000). In both scenarios, there will be no contact
with medical facilities (Kilian 2003). In these cases, innovations
that do not rely on the presence of health staff will be particularly
useful.
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This review has examined the use of one specific type of packaging,
unit-dose packaging. To make patients more aware of when to
take each tablet, a full course of therapy is presented in a single
pack, with the drugs to be taken together adjacent to each other,
sometimes with markings or colours to indicate that they should
be taken all at once; see Figure 1, Figure 2, Figure 3, and Figure 4
for examples.
Figure 1. Sectioned polythene bags of chloroquine (from Ghana)
4Unit-dose packaged drugs for treating malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Blister-packed sulfadoxine-pyrimethamine and amodiaquine (from Rwanda)
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Figure 3. Blister-packed artesunate and mefloquine (from Cambodia)
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Figure 4. Blister-packed artemether-lumefantrine (trade name Coartem, Novartis)
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Analysing the effectiveness of unit-dose
packaging
In reality, unit-dose packaging is not likely to be provided as a
single adherence intervention. Often, combining various inter-
connecting strategies helps ensure that the best patient outcomes
can result (Haynes 1996). This must be taken into account when
analysing which interventions are successful in which settings, and
when defining, developing, documenting, and reproducing the
interventions.
In addition, any difference in malaria cure rates or adherence lev-
els between the intervention and control groups could be due to
either the intervention (unit-dose packaging) or to the non-spe-
cific effects of increased attention paid to the intervention group.
Depending on where and when the drugs are acquired, some form
of health education may be given alongside the provision of an-
timalarial drugs. With the introduction of new unit-dose pack-
aged drugs, this health education may be more extensive and clear
(structured and backed up by the pack, helping to reinforce mes-
sages). It could be that the packaging is a useful co-intervention
that increases provider instruction to the patient. It may also help
private sellers with little medical knowledge to give correct infor-
mation. This may be the mechanism for an effect on treatment
adherence and cure rates. For the purpose of this review, we have
assessed the extent to which co-interventions (including informa-
tion and education) have been reported and controlled for, and
when “usual care” or “normal practice” was quoted as the control
intervention we checked that this was adequately defined.
The aim of any adherence promotion in malaria treatment is to
improve malaria cure rates (as measured by treatment failure), and
we have used this as our primary outcome measure. Furthermore,
while adherence to correct doses of malaria treatment has been
found to correlate with improvement in the condition of patients
(Okonkwo 2001), no clear connection has been found between
malaria treatment adherence and cure (and some people may be
cured at less than 100% adherence). Malaria cure rate may be im-
proved with increased adherence, but we cannot guarantee that
this is the mechanism for any observed change. Ensuring optimal
treatment adherence may also help slow the development of para-
site drug resistance by ensuring the correct drug concentration in
the blood and the quickest cure, but we have not addressed this
issue in the current review. Some researchers have hypothesized
that as increased adherence to treatment will mean patients receive
on average a higher dose of the drug, this may lead to an increase
in the incidence of some adverse events. Hence, the current review
also assesses the incidence of adverse events, where reported.
Malaria illness can take two forms, uncomplicated malaria and
severe malaria. The most common symptom of uncomplicated
malaria is fever, although patients may also complain of headache,
aches and pains elsewhere in the body, and occasionally of abdom-
inal pain and diarrhoea. Severe malaria is caused by infection with
P. falciparum and usually occurs as a result of delay in treating an
uncomplicated attack of falciparum malaria (WHO 2000). This
review has examined the use of unit-dose packaging for treating
uncomplicated malaria only. Severe malaria is normally treated
in the hospital or clinic setting with intravenous drugs; whether
unit-dose packaging interventions have an effect on treatment out-
comes in this setting is a different question.
Randomized controlled trials are rarely used to investigate com-
plex interventions such as drug packaging. Most investigators use
a community design, but it is often difficult to determine the treat-
ment effect in this trial design. We have therefore not included
community studies in this review, but we have discussed any perti-
nent observations made in such studies in the context of the main
findings of the review.
O B J E C T I V E S
To summarize the effects of unit-dose packaged treatment on treat-
ment failure and treatment adherence in people with uncompli-
cated malaria.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs), and quasi-RCTs; including
trials randomized by cluster.
Types of participants
People diagnosed (clinically or confirmed with microscopy) with
uncomplicated malaria infection (as defined by the trial authors).
Types of interventions
Intervention
Any programme that includes unit-dose packaging of antimalarial
drugs, that is, drugs packed in units of a single dose.
Control
Standard practice before the intervention, or alternative packaging
intervention.
Intervention and control arm to receive the same antimalarial drug
and any other interventions.
Types of outcome measures
Primary
Treatment failure on or by day 28: (1) including new infections
and (2) adjusted to exclude new infections (detected by PCR).
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Secondary
Treatment failure on or by day 14: (1) including new infections
and (2) adjusted to exclude new infections (detected by polymerase
chain reaction (PCR)).
Treatment adherence: participants completing the full treatment
regimen, as approximated by the trial authors (for example, by pill
counts or residual syrup measurement; patient interview; or drug
concentration in urine or plasma).
Adverse events
• Serious adverse events (fatal, life threatening, or require
hospitalization).
• Adverse events that result in the discontinuation of
treatment.
• Any other adverse events.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and in
progress).
Databases
We searched the following databases using the search terms and
strategy described in Appendix 1. Cochrane Infectious Diseases
Group Specialized Register (February 2009); Cochrane Central
Register of Controlled Trials (CENTRAL), published in The
Cochrane Library (Issue 1, 2009); MEDLINE (1966 to February
2009); EMBASE (1974 to February 2009); and LILACS (1982
to February 2009)
Conference proceedings
We searched the following conference proceedings for relevant ab-
stracts: The Third Multilateral Initiative on Malaria Pan-African
Conference, Arusha, Tanzania, 18 to 22 November 2002; The
Third EuropeanCongress on Tropical Medicine and International
Health, Lisbon, Portugal, 8 to 12 September 2002; and The In-
ternational Conference on Malaria: Current Status and Future
Trends, Bangkok, Thailand, 16 to 19 February 2003; the Fourth
Multilateral Initiative on Malaria Pan-African Conference (Roll
Back Malaria), Yarounde, Cameroon, 13 to 18 November 2005;
the Fifth European Congress on Tropical Medicine and Interna-
tional Health, Amsterdam, the Netherlands, 24 to 28 May 2007;
Stop Malaria Now! (an African-European Initiative) International
Malaria Conference, Bonn, Germany, 21 to 22 April 2008.
Researchers, organizations, and pharmaceutical
companies
For unpublished and ongoing studies, we contacted individual re-
searchers working in the field, theWHO, and the pharmaceutical
companies GlaxoSmithKline, Merck, and Novartis (May 2009).
Reference lists
We also checked the reference lists of all studies identified by the
above methods.
Data collection and analysis
Selection of studies
LoisOrton assessed the results of the literature search and obtained
the full reports for all potentially relevant studies. Both authors
independently assessed the potentially relevant studies for inclu-
sion using an eligibility form based on the inclusion criteria. We
scrutinized all potentially eligible studies for duplicate publication
from the same data set, and resolved disagreements through dis-
cussion and, when necessary, by consulting a Cochrane Infectious
Diseases Group Editor.We stated the reasons for excluding studies
in the ’Characteristics of excluded studies’.
We described the usability of drug packaging (for literate and non-
literate people) using the following criteria (seeking further infor-
mation from trial authors where necessary): regimen; packaging
type; labelling and instructions on pack; and dosage presentations
for age or weight categories.
We examined each trial to identify the presence of any possible co-
interventions, apart from the primary intervention. This included
any health education (formal or informal), training, advice, poster,
television or radio promotion, follow up, or support. We took this
into consideration in the assessment of the efficacy of the primary
intervention.
Data extraction and management
Both authors independently extracted data on the methods, types
of participants, interventions, and outcomes. We compared the
two sets of extracted data and discussed them to ensure accuracy
and completeness. Where necessary, we sought the opinion of a
Cochrane Infectious Diseases Group Editor to resolve any dis-
agreements. Where required, we requested additional data from
the trial authors.
As packaging interventions may be complex and unique, we also
extracted additional information that helps the reader to under-
stand the specific characteristics of the intervention.
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Assessment of risk of bias in included studies
We independently assessed themethodological quality of each trial
based on the guidance given in the Cochrane Handbook for System-
atic Reviews of Interventions Higgins 2008, and using the criteria
outlined below, resolving disagreements through discussion. We
displayed this information in a table and described it in the ’Risk
of bias in included studies’.
We assessed the generation of the allocation sequence and alloca-
tion concealment as adequate, inadequate, or unclear according
to Juni 2001. We considered the completeness of outcome data
to be adequate if it was greater than 80%. We classified assessor
blinding (all other types of blinding are redundant with pre-pack-
aging interventions) as present, absent, or unclear.
Data synthesis
We undertook a descriptive interpretation of results. We described
all possible sources of heterogeneity between the interventions ac-
cording to the criteria outlined above under description of inter-
vention. Where possible, we also pooled the data in a meta-anal-
ysis using the methods described below.
We used Review Manager 5.0 (RevMan 2008) to make compar-
isons between the treatment and control groups in an intention-
to-treat analysis. We combined binary data using risk ratio (RR)
and the fixed-effect model and presented them with 95% confi-
dence intervals (CIs). We assessed heterogeneity by visually exam-
ining the forest plots and by using the Chi2 test for heterogeneity
with a 5% level of statistical significance, but detected none.
We will use the following planned analyses, which were not re-
quired in this version because of insufficient studies, when we up-
date this review with new trials. (1) We will analyse continuous
data using the mean difference with 95% confidence intervals. (2)
If we detect statistically significant heterogeneity, and it is still ap-
propriate to pool the data, we will use the random-effects model.
(3) We will explore potential sources of heterogeneity using sub-
group analyses based on the criteria outlined under description of
intervention, and the proportion of participants known to have
completed the full treatment regimen. (4) We will conduct sensi-
tivity analyses on the basis of trial methodological quality (using
the quality criteria outlined above) and the adequacy of reporting
of co-interventions (in particular, whether or not it was explicitly
verified that an equal level of concomitant health education was
provided in the intervention and control arms of the trial). (5) We
will consider publication bias using a funnel plot.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We identified 57 articles from the search strategy and excluded 45
after scanning the titles. The remaining 12 papers reported 13 po-
tentially relevant studies, of which eight did not meet the inclusion
criteria (seeCharacteristics of excluded studies). Five trials met our
inclusion criteria (Li 1998a; Li 1998b; Yeboah-Antwi 2001; Ansah
2003; Lauwo 2006); they are detailed in the ’Characteristics of
included studies’ and summarized below.
Included studies
Trial design and location
Lauwo 2006 did not state the method of randomization used;
Li 1998a, Li 1998b, and Ansah 2003 used alternate allocation
techniques to allocate individuals, and Yeboah-Antwi 2001 ran-
domized health facilities (cluster-randomization). Li 1998a and Li
1998b were conducted in Health and Epidemic Prevention Sta-
tions in Hunan Province, China, where malaria transmission is
epidemic, with migration allowing imported cases. Lauwo 2006
was conducted in Papua New Guinea where malaria transmis-
sion is high and perennial. The other trials were conducted in
Ghana: Ansah 2003 in Cape Coast, where malaria is highly en-
demic and perennial; and Yeboah-Antwi 2001 inWenchi District,
where malaria transmission is intense and stable with slight sea-
sonal variation.
Participants
RCTs
Lauwo 2006 randomized 203 adults with clinically and micro-
scopically confirmedmalaria into three treatment groups.We have
excluded one treatment group because participants did not receive
the same counselling co-intervention as the other groups.
Quasi-RCTs
Ansah 2003 randomized 299 children with clinically confirmed
malaria to two treatment groups. Li 1998a and Li 1998b ran-
domized 596 adults with slide-confirmed P. vivax malaria to two
treatment groups. Li 1998b was conducted two years later in the
same region as Li 1998a, but when we contacted the trialists, they
clarified that no participant was included in both trials.
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Cluster-RCT
Yeboah-Antwi 2001 randomized six health facilities into two treat-
ment groups. At these facilities, 616 children and adults with clin-
ical malaria were recruited. Participants up to six years were given
syrup, and those over six years received tablets. We have only in-
cluded data for the 319 participants who received tablets, as the
syrup was not unit-dose packaged.
Interventions
Li 1998a and Li 1998b provided labelled and boxed blister packs of
chloroquine and primaquine tablets and capsules; Yeboah-Antwi
2001, Ansah 2003 and Lauwo 2006 provided simple labelled and
sectioned polythene bags of chloroquine tablets (Yeboah-Antwi
2001; Ansah 2003, seeAppendix 2) or chloroquine and sulphadox-
ine-pyrimethamine tablets (Lauwo 2006). In Li 1998a, Li 1998b,
and Yeboah-Antwi 2001 control participants received tablets or
capsules in paper envelopes or loose, while in Ansah 2003 control
participants received chloroquine syrup in bottles and in Lauwo
2006 control participants received chloroquine and sulphadoxine-
pyrimethamine tablets in separate polythene bags with pen-writ-
ten instructions.
Ansah 2003 trained prescribers in using a chart, showing the ap-
propriate dosage by weight, to demonstrate to caregivers how to
give the medicine. Yeboah-Antwi 2001 trained intervention and
control facility staff in prescribing and dispensing; all participants
were given the same counselling in how to take the drug, but par-
ticipants at the intervention facilities were given additional coun-
selling. Li 1998a trained staff to give similar oral instructions at
the intervention and control facilities. Lauwo 2006 provided staff
with a written script containing information, questions, and spe-
cial instruction including information on the risks associated with
malaria if it was not quickly and appropriately treated, and on the
need to adhere tomedication directions, to complete treatment, to
seek further medical attention if adverse effects were experienced,
and to return to the hospital if there was no improvement after
completion of the medication. Li 1998b did not provide any data
about staff training or patient information. Participants were given
the drugs to take at home in Li 1998a and Li 1998b; in Yeboah-
Antwi 2001 they were observed taking the first dose at the health
centre; and in Ansah 2003 and Lauwo 2006 it is unclear where
participants took the drugs.
Outcomes
None of the trials reported on the primary outcomemeasure, treat-
ment failure, as defined in the inclusion criteria. Instead, Li 1998a
tested for parasitaemia and clinical symptoms at day nine (eight-
day regimen), Lauwo 2006 reported cure according to medical
notes (undefined) and participants’ perception at day four of a
three-day regimen, and Ansah 2003 and Yeboah-Antwi 2001 as-
sessed wellness of the child at day four (three-day regimen). Mea-
surements taken at such early time points will not pick up relapses
and recrudescence of infection. In an attempt to overcome this,
Li 1998b followed a subset of 57 participants to day 100. All five
trials measured treatment adherence (which they termed “com-
pliance”) through participant interview. Yeboah-Antwi 2001 also
measured the remaining drugs at the end of the treatment course,
and Li 1998b marked the drugs with phenobarbital and measured
its level in the blood as an indicator of treatment adherence.
Yeboah-Antwi 2001 and Ansah 2003 recorded some adverse
events, while Li 1998a, Li 1998b, and Lauwo 2006 did not mea-
sure the incidence of adverse events.
Risk of bias in included studies
See the ’Characteristics of included studies’ for details about the
methodology, and Appendix 3 for the risk of bias assessment.
Only the cluster-RCT, Yeboah-Antwi 2001, used an adequate
method to generate the allocation sequence. The three quasi-
RCTs, Li 1998a, Li 1998b, and Ansah 2003, used alternate allo-
cation, and Lauwo 2006 did not state the method used. None of
the trials provide any details of the method of allocation conceal-
ment, although allocation was not likely to have been concealed in
the quasi-RCTs as the method of alternate allocation would lead
to a predictable allocation sequence. The outcome assessor was not
blinded in any of the trials (trialists provided additional data for
Li 1998a and Li 1998b). It was not possible to blind participants
or healthcare providers in Yeboah-Antwi 2001 but, as the health
facilities were far apart and communication was not good, it is
unlikely that treatment allocation would influence participants in
their choice of facility (intervention or control). It was only pos-
sible to calculate the completeness of outcome data for two of
the trials, Ansah 2003 and Lauwo 2006. Ansah 2003 included
99% of the participants in the analysis, which we considered to be
adequate, and Lauwo 2006 included 73%, which we considered
to be inadequate.
The cluster-RCT, Yeboah-Antwi 2001, used three intervention
and three control groups and treated the data as if it came from a
trial that randomized individuals (not taking account of the clus-
tering). As participants recruited at the same facility are likely to
be more similar than participants recruited at different facilities,
there is likely to be a high level of correlation between trial partic-
ipants, which the trialists have not evaluated or considered.
Effects of interventions
Blister packs versus paper envelopes: 596
participants, two quasi-RCTs
Although the trials did not assess treatment failure, Li 1998a
found that all 324 participants (intervention and control) were
aparasitaemic and asymptomatic at day nine of an eight-day reg-
imen, and Li 1998b found that one of the 57 participants still
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available for follow up at day 100 had recrudesced at day 88 (con-
trol group; reported not to have completed treatment).
A combined estimate from the two trials found that 18% more
participants in the group using blister packs reported that they
adhered to the full regimen (measured by participant interview),
which is statistically significant (RR 1.18, 95% CI 1.12 to 1.25;
596 participants; Analysis 1.1). Li 1998b analysed the data sep-
arately for each drug and found a statistically significant differ-
ence, in favour of the intervention, in both drug groups (chloro-
quine 67/69 versus 56/67, P value < 0.05; primaquine 67/69 ver-
sus 49/67, P value 0.05; trialists’ values). Li 1998b also measured
drug marker levels and found no statistically significant difference
in the median phenobarbital level-to-dose ratio between the in-
tervention and control groups (trialists’ data; see Appendix 4).
Sectioned polythene bags versus bottled syrup: 299
participants, one quasi-RCT
Ansah 2003 did not measure treatment failure, but by day four
of the three-day regimen most participants were considered fully
recovered by their caregivers (intervention 144/155 versus control
137/144).
Participant-reported treatment adherence (measured by partici-
pant interview) was 115% higher in those receiving tablets in sec-
tioned polythene bags than in those receiving bottles of syrup (RR
2.15, 95% CI 1.76 to 2.61; 299 participants; Analysis 2.1). The
volume of the instrument used to dispense the syrup to control
participants was not considered in the assessment of adherence.
This was found to vary from 1ml to 9 ml, and most were less than
the recommended 5 ml; when the trialists took spoon volume into
account, only 12/140 of the control participants had taken the
recommended 25mg/kg total dose by day four, but not necessarily
according to the prescribed dosage schedule.
The trialists did not collect adverse event data systematically. Of
the 155 participants receiving tablets, 28 vomited some medica-
tion and six vomited all tablets. The trialists reported that if those
participants who vomited their tablets were considered non-ad-
herent, the difference in adherence between intervention and con-
trol is still statistically significant (76% versus 42%).
Sectioned polythene bags versus paper envelopes: six
clusters, one cluster-RCT
Yeboah-Antwi 2001 did not assess treatment failure, but they re-
ported that most participants’ wellness had improved by day four
of the three-day regimen (intervention: 152 improved, 13 un-
changed, two worsened; control: 143 improved, four unchanged,
five worsened).
Treatment adherence (measured by participant interview and
drug inspection) was higher in the group receiving tablets in sec-
tioned polythene bags than in those receiving tablets in paper en-
velopes (137/167 intervention versus 92/152 control). Although
reported as statistically significant, the trialists analysed the data
without taking account of clustering, so the true result may not
be.
The trialists reported a similar incidence of itching, dizziness, and
other adverse events. They did not collect these data systemati-
cally, but reported them when given as a reason for not taking the
drugs as recommended (see Appendix 5).
Sectioned polythene bags versus polythene bags
(unsectioned)
Lauwo 2006 did not assess treatment failure, but reported no
significant difference in the cure rate at day four (intervention
77/91 versus control 96/112).
There was no statistically significant difference in treatment ad-
herence between treatment groups (measured by participant in-
terview; Analysis 3.1). However, the authors found both inter-
vention and control group participants to have better adherence
than a further control group which received neither packaging nor
counselling.
D I S C U S S I O N
There is insufficient good quality evidence to determine the effect
of unit-dose packaged antimalarial drugs on treatment failure, but
five small trials suggest that some designs may improve adherence
to treatment for uncomplicated malaria when supported by pre-
scriber training and patient information. However, the reliability
of these conclusions is limited by the methodological quality of
the trials that inform it.
Of the five RCTs that met our inclusion criteria, we were only able
to calculate the number of randomized participants included in
the analysis for two of them. Four used an inadequate or unclear
method of allocation sequence generation, and the other random-
ized health facilities rather than patients. This cluster-RCT in-
cluded only a small number of health facilities, which reduces the
statistical power of the trial, as it is likely that data for participants
recruited at the same treatment facility will be more correlated
than data for participants recruited at different facilities. In fact,
the trialists ignored the possibility that data for participants were
correlated in the analyses and, as such, this trial may overestimate
the treatment effect. None of the trials blinded the outcome as-
sessor, and it is likely that most trials did not conceal allocation
of treatment, which allows the potential for bias. While there are
limitations in the interpretation of the results of the included trials,
they are supported by some observational studies that also suggest
an improvement in adherence with the introduction of packaged
antimalarial drugs (Browne 2001; Sirima 2003).
Patient interview was the predominant method used to approxi-
mate treatment adherence in the included trials (one trialist veri-
fied this measure by inspecting left-over drugs). This is subject to
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bias, as participants will not always recall accurately how they took
the drug. Another way to estimate what treatment was taken is
to measure drug concentrations in the blood. However, this only
provides a snap shot of medication taking. Reliable approaches
to measuring treatment adherence are needed in order to assess
the effects of adherence interventions accurately, such as unit-dose
packaging.
Most of the included trials assessed treatment adherence in terms
of the participants drug-taking behaviour in relation to the treat-
ment guidelines. Although efforts were made by the trial authors
to verify that prescribers were also adhering to the treatment guide-
lines this is difficult to ensure and, therefore, non-adherence could
be due to either prescriber or patient error. Yeboah-Antwi 2001
looked at prescribers’ ability to adhere to treatment guidelines and
found that despite a background training session conducted for
all prescribers (at intervention and control facilities), more par-
ticipants at the intervention facilities were prescribed the correct
doses. This suggests that unit-dose packaging interventions help
both the prescriber and the patient.
Some investigators have developed interventions for packaging
paediatric syrup by addingdosingdiagrams and spoons (Okonkwo
2001; Yeboah-Antwi 2001), but at present no unit-dose style pack-
aging has been developed for syrup. Others have begun examining
the use of unit-dose packaged tablets for children instead. Ansah
2003 compared unit-dose packaged tablets with bottled syrup,
and found a large improvement in adherence. The increased ease
of dosage due to a change from syrup to tablets will probably
have played a large part in the observed effect in this trial. The
caregivers involved in this trial accepted and even preferred tablets
for their children (Ansah 2003). There was a slight problem with
some children vomiting tablets. Investigators addressed this con-
cern by suggesting caregivers crush and mix the tablets with sugar.
However, as Standing 2004 asserts, it has not been shown that this
method adequately delivers the drug, especially as the tablets have
also been snapped in order to dose the children correctly. This
is known to lead to wastage. One way to overcome this problem
may be tomanufacture special paediatric formulations, or to focus
efforts on helping mothers to dose syrup correctly.
The design of packaging interventions, and the context in which
they are used, is diverse and care should be taken when general-
izing conclusions about their effectiveness from one design to an-
other or from one region to another. Good drug-packaging design
is informed by users’ needs. Qualitative investigation has shown
that unit-dose packaged drugs are generally acceptable or even pre-
ferred (Ansah 2003), but further studies should help determine the
most effective design and elucidate which co-interventions help
maximize this effectiveness within and between treatment settings.
Prescriber training and patient information is likely to be a critical
factor in how well such interventions work in practice. In these
trials, while it was usually intended for staff at the intervention
and control facilities to receive comparable levels of training, it
often transpired that staff at the intervention facilities received
more comprehensive training and therefore gave the patients more
comprehensive information. It is likely that the pack was used to
guide the information given to patients. It was new and had to
be explained. In fact, the Okonkwo 2001 trial found a significant
difference in adherence between packaged drugs with verbal in-
structions and packaged drugs without verbal instructions (pack-
aging not unit dose in this trial).
Normal practice circumstances are likely to differ dramatically
from trial conditions. All trials included in this review were con-
ducted intensively in a small locality, using a small number of
government health facilities. Most prescribers were fairly highly
qualified and were given training in how to dispense the unit-
dose packaged drugs with information to help patients take them
correctly. If interventions such as these are going to be used in a
wider setting, for example with multinationals producing packs
on a large scale, the same level of one-to-one training is not likely
to be provided to prescribers and dispensers, and the packs will
have to work in a variety of settings in which they are unlikely to
have been tested.
There is also the challenge of designing packs that can be used
effectively in more rural settings. Here, drugs are more likely to
be distributed by unregulated (normally unqualified) private drug
vendors. In fact, some episodes of malaria will be treated in the
home using leftover drugs without any contact with a health fa-
cility or drug vendor. In both of these situations, the packs will
either have to be designed to stand alone (with no supportive co-
interventions) or shopkeepers will have to be trained in dispens-
ing. As it is not always possible to ensure a good level of prescriber-
patient information, sector-wide supportive interventions may be
a useful tool to help increase the general awareness of unit-dose
packaged drugs (Marsh 2004). TheWHOhas recognized this and
are preparing recommendations that packaged drugs be given as
part of wider Information, Education, and Communication cam-
paigns involving, for example, schools, printed posters, and tele-
vision (Browne 2001).
We have found only five trials investigating the unit-dose packag-
ing of malaria treatment. These trials all used chloroquine-based
therapies, regimens which are no longer recommended for use
in the treatment of uncomplicated falciparum malaria (WHO
2006). While all trials appear to show an increase in participant-
reported adherence with unit-dose packaged drugs, they did not
demonstrate an effect on treatment effectiveness and patient out-
comes. Three of the four included trials used combination therapy
(chloroquine-based) (Li 1998a; Li 1998b; Lauwo 2006).However,
in Li 1998a and Li 1998b the investigators did not optimize the
potential of the packaging by presenting the drugs together in one
pack. With the spread of multiple-drug resistant malaria, it would
be useful to know how effective unit-dose packaging is when used
with the currently recommended artemisinin-based combination
therapies (ACTs). As the majority of deaths due to malaria occur
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in children aged five years and under, efforts should be targeted at
developing paediatric packs.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Trials of unit-dose packaged antimalarial drugs have not assessed
treatment failure. When supported by prescriber training and pa-
tient information, some package designs appear to improve partic-
ipant-reported treatment adherence in the settings in which they
have been tested. However, some methodological limitations of
the included trials should be taken into consideration when inter-
preting these findings.
Implications for research
Unit-dose packaging interventions are complex interventions.
Qualitative investigations could help determine the most repro-
ducible and the most effective designs. Ideally, packs should be
developed with input from the local community, with due con-
sideration for the settings in which they will be employed and the
need for any additional interventions (such as educational pro-
grammes) to help optimize their effectiveness.
Good quality RCTs of unit-dose packaged combination therapies
for malaria, particularly of formulations for children under five,
are urgently needed. Investigators should assess treatment failure
and adverse events, not just treatment adherence. There is a need
to develop reliable methods of estimating treatment adherence in
these trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ansah 2003
Methods Quasi-randomized controlled trial
Generation of allocation sequence: alternate allocation
Allocation concealment: no information provided
Blinding of outcome assessor: none
Completeness of outcome data: 99%
Participants Participants: 299 analysed (155 intervention; 144 control); 301 initially recruited
Inclusion criteria: aged 0 to 5 years; brought to 1 of 2 clinics with malaria
Exclusion criteria: none given, but 2 participants excluded on developing severe malaria
Mean age: not stated
Age range: not stated
Male to female ratio: not stated
Education: not stated
Interventions See Appendix 2 for details
Outcomes 1. Treatment adherence: number of participants following the prescribers’ exact instructions in terms of dosage
(spoon size for syrup not taken into account), frequency of daily administration, and duration of treatment;
measured by participant interview
2. Caregivers’ assessment of wellness at day 4
3. Vomiting of tablets
Not included in review:
1. Packaging acceptability and preference
2. Financial and economic costs
Notes Location: Cape Coast, Ghana
Health facilities: 2 public health centres
Endemicity: highly endemic malaria
Antimalarial drug resistance: not stated
Malaria diagnosis: clinical (Plasmodium falciparum causes most morbidity and mortality in this area)
Lauwo 2006
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: no information provided
Blinding of outcome assessor: none
Completeness of outcome data: 73%
Participants Participants: 103 analysed (91 intervention; 112 control); 180 initially recruited
Inclusion criteria: adult; clinical and microscopic diagnosis of malaria; prescribed standard antimalarial drugs; spoken
and understood English, Tok Pisin or Motu
Exclusion criteria: inability to return for follow-up interview on day 4
Mean age: not stated
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Lauwo 2006 (Continued)
Age range: not stated
Male to female ratio: 242:194
Education: not stated
Interventions see Appendix 2 for details
Outcomes 1. Treatment failure at day 4
2. Treatment adherence at day 4: interview - good adherence if remember instructions and complete medication as
prescribed or directed
Not included in review:
3. Health professionals’ reactions to the packaging
Notes Location: Port Moresby, Papua New Guinea
Health facilities: outpatient department of Port Moresby General Hospital
Endemicity: not stated
Antimalarial drug resistance: chloroquine and amodiaquine
Malaria diagnosis: clinical and microscopic
Li 1998a
Methods Quasi-randomized controlled trial
Generation of allocation sequence: alternate allocation
Allocation concealment: no information provided
Blinding of outcome assessor: none
Completeness of outcome data: number analysed provided but number recruited not provided
Participants Participants: 324 analysed (161 intervention; 163 control); no data provided on how many participants were initially
recruited
Inclusion criteria: slide positive for Plasmodium vivax malaria; aged > 15 years; ambulatory
Exclusion criteria: major clinical symptoms requiring hospitalization; malaria treatment in the previous 6 months
Mean age: 31 years
Age range: 16 to 63 years
Male to female ratio: 300:24
Education: not stated
Interventions See Appendix 2 for details
Outcomes 1. Treatment adherence: number of participants completing full treatment; measured by participant interview
2. Participants tested for parasitaemia at day 9
Notes Location: Hunan province, China
Health facilities: staff highly qualified, each station had good working relationship with provincial authorities
Endemicity: epidemic (imported) malaria
Antimalarial drug resistance: not stated
Malaria diagnosis: microscopically confirmed Plasmodium vivax malaria
18Unit-dose packaged drugs for treating malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Li 1998b
Methods Quasi-randomized controlled trial
Generation of allocation sequence: alternate allocation
Allocation concealment: no information provided
Blinding of outcome assessor: none
Completeness of outcome data: number analysed provided but number recruited not provided
Participants Participants: 272 analysed (138 intervention; 134 control); no information provided on the number of participants
initially recruited
Inclusion criteria: slide positive for Plasmodium vivax malaria; aged > 15 years; ambulatory
Exclusion criteria: major clinical symptoms requiring hospitalization; malaria treatment in the previous 6 months
Mean age: not stated
Age range: 11 to 67 years
Male to female ratio: mostly male
Education: not stated
Interventions See Appendix 2 for details
Outcomes 1. Treatment adherence: adherence to chloroquine at day 4 and to primaquine at day 9; measured by participant
interview and phenobarbital marker level-to-dose ratios (for each drug separately and for both drugs together)
2. Recrudescence at days 1 to 100
Not included in review:
1. Reasons for non-adherence
Notes Location:Hunanprovince,China; conducted in same region as Li 1998a, but different participants (clarified following
correspondence with trialists)
Health facilities: staff highly qualified, each station had good working relationship with provincial authorities
Endemicity: epidemic (imported) malaria
Antimalarial drug resistance: not stated
Malaria diagnosis: microscopically confirmed Plasmodium vivax malaria
Yeboah-Antwi 2001
Methods Cluster-randomized controlled trial
Generation of allocation sequence: adequate
Allocation concealment: no information provided
Blinding of outcome assessor: none
Completeness of outcome data: number analysed provided but number recruited unclear
Trialists did not take clustering into account in the analysis of this cluster-randomized controlled trial
Participants Participants: facilities randomized rather than participants; 3 intervention facilities (262 participants) and 3 control
facilities (247 participants); 190 participants excluded from this review as they did not receive unit-dose packaged
drugs; unclear how many were recruited initially
Inclusion criteria: diagnosed with malaria; treated with chloroquine; living in the town of the facility
Exclusion criteria: diagnosed as having malaria but not treated with chloroquine; living outside the town where the
facility is located
Mean age: not stated
Age range: adults and children (7+ years)
Male to female ratio: 197:312
Education: 309 none; 170 primary; 30 other
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Yeboah-Antwi 2001 (Continued)
Note: these data are for the entire trial; we have excluded participants receiving syrup from the review
Interventions See Appendix 2 for details
Outcomes 1. Treatment adherence: number completing full treatment in relation to given treatment guidelines. Measured
by patient interview and drug inspection
2. Wellness at day 4: participants asked if they were feeling better, same, or worse compared to the day they went
to the clinic/hospital
3. Adverse events (reasons for non-adherence/withdrawal)
Not included in review:
1. Packaging perceptions and acceptance
2. Some costs data
Notes Location: Wenchi District, Brong Ahafo Region, Ghana
Health facilities: no data available
Endemicity: intense stable malaria transmission with slight seasonal variations (45.9% to 46.8%)
Antimalarial drug resistance: chloroquine resistance said to be low (only drug used at health centres, health posts and
rural clinics)
Malaria diagnosis: confirmed clinically (Plasmodium falciparum is the main cause of morbidity and mortality in this
region)
Characteristics of excluded studies [ordered by study ID]
Agyepong 2002 This trial was not controlled
Browne 2001 This trial was not controlled
Cullinan 1997 Participants included in this trial had severe malaria
Krudsood 2002 Both treatment groups received identical packaging intervention
Okonkwo 2001 The packaging used in this trial was not unit-dose packaging
Pagnoni 1997 This trial was not controlled
Shwe 1998 Both treatment groups received identical packaging interventions
Sirima 2003 This trial was not controlled
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D A T A A N D A N A L Y S E S
Comparison 1. Blister-packed tablets and capsules versus tablets and capsules in paper envelopes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment adherence (measured
by interview)
2 596 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.12, 1.25]
Comparison 2. Tablets in sectioned polythene bags versus bottled syrup
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment adherence (measured
by interview)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 3. Tablets in sectioned polythene bags versus polythene bags (unsectioned)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment adherence (measured
by interview)
1 203 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.95, 1.09]
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Analysis 1.1. Comparison 1 Blister-packed tablets and capsules versus tablets and capsules in paper
envelopes, Outcome 1 Treatment adherence (measured by interview).
Review: Unit-dose packaged drugs for treating malaria
Comparison: 1 Blister-packed tablets and capsules versus tablets and capsules in paper envelopes
Outcome: 1 Treatment adherence (measured by interview)
Study or subgroup Blister packs Paper envelopes Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Li 1998a 156/161 136/163 55.2 % 1.16 [ 1.08, 1.25 ]
Li 1998b 134/138 108/134 44.8 % 1.20 [ 1.10, 1.32 ]
Total (95% CI) 299 297 100.0 % 1.18 [ 1.12, 1.25 ]
Total events: 290 (Blister packs), 244 (Paper envelopes)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 5.74 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours envelopes Favours blister pack
Analysis 2.1. Comparison 2 Tablets in sectioned polythene bags versus bottled syrup, Outcome 1
Treatment adherence (measured by interview).
Review: Unit-dose packaged drugs for treating malaria
Comparison: 2 Tablets in sectioned polythene bags versus bottled syrup
Outcome: 1 Treatment adherence (measured by interview)
Study or subgroup Sectioned bags Bottles Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ansah 2003 141/155 61/144 2.15 [ 1.76, 2.61 ]
0.2 0.5 1 2 5
Favours bottles Favours bags
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Analysis 3.1. Comparison 3 Tablets in sectioned polythene bags versus polythene bags (unsectioned),
Outcome 1 Treatment adherence (measured by interview).
Review: Unit-dose packaged drugs for treating malaria
Comparison: 3 Tablets in sectioned polythene bags versus polythene bags (unsectioned)
Outcome: 1 Treatment adherence (measured by interview)
Study or subgroup Sectioned bags Bags Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lauwo 2006 86/91 104/112 100.0 % 1.02 [ 0.95, 1.09 ]
Total (95% CI) 91 112 100.0 % 1.02 [ 0.95, 1.09 ]
Total events: 86 (Sectioned bags), 104 (Bags)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
0.01 0.1 1 10 100
Favours sectioned bags Favours bags
A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 packaging drug packaging drug packaging drug packaging drug packaging
2 malaria tablet DRUG PACKAGING DRUG PACKAGING malaria
3 - capsule tablet DRUG DOSAGE
FORM
1 and 2
4 - syrup capsule tablet -
5 - blister pack syrup TABLET -
6 - unit dose pack blister pack capsule -
7 - 1 or 2 or 3 or 4 or 5 or 6 unit dose pack syrup -
8 - malaria 1 or 2 or 3 or 4 or 5 or 6
or 7
blister pack -
9 - 7 and 8 malaria unit dose pack -
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(Continued)
10 - - MALARIA 1 or 2 or 3 or 4 or 5 or 6
or 7 or 8 or 9
-
11 - - 9 or 10 malaria -
12 - - 8 and 11 MALARIA -
13 - - - 11 or 12 -
14 - - - 10 and 13 -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Alderson
2004); upper case MeSH or EMTREE heading; lower case: free text term.
Appendix 2. Interventions
Trial Regimen Packaging type Labels/
instructions
Training/
counselling
Dosage
presentation
Ansah 2003 3-day regimen of
chloroquine
Intervention: tablets
Control: syrup
Intervention:
hermetically sealed,
sectioned polythene
bags with daily dose
of tablets in each
section
Control: bottles of
syrup
Intervention: each
section labelled 1, 2,
3 (day to be taken)
Control: unclear
Intervention and
control: prescribers
given chart showing
appropriate dosage
by weight; trained
in using chart to
tell caregivers how
to give the medicine
Interven-
tion: 8 dosage pre-
sentations available
(by weight)
Control: no dosage
presentations; all re-
ceive 60 ml syrup
and instructed to
give weight-tailored
dose
Lauwo 2006 3-day regi-
men of chloroquine,
plus sulphadoxine-
pyrimethamine on
the first day
Intervention: tablets
Control: tablets
Intervention: sealed
clear sectioned poly-
thene bags stapled
to card base with
daily dose of tablets
in each colour-
coded section
Control: sep-
arate polythene bags
for chloroquine and
sulphadoxine-
pyrimethamine
Intervention:
name of drugs and
instructions written
under each section
Control: pen-writ-
ten instructions
Inter-
vention and control:
counselling given by
intern pharma-
cists from written
script covering risks
of malaria if treated
quickly and appro-
priately; need to ad-
here to medication
directions, to com-
plete treatment, to
seek further medical
attention if experi-
Intervention:
no dosage presenta-
tions available
Control: no dosage
presentations avail-
able
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(Continued)
ence adverse events;
and to return to out-
patients if no im-
provement
Li 1998a 1. 3-day regimen of
chloroquine
2. 8-day regimen of
primaquine
Intervention and
control: tablets
In-
tervention: 1 boxed
blister pack for each
drug course; tablets
to be taken each day
together in 1 blister
Control: paper en-
velopes
Intervention: drug
name on blister
pack (back) and box
(front); dosage in-
structions and pre-
cautions on back
of box; instruction
leaflet inside box
Control: none
Intervention: health
staff trained
to give oral instruc-
tions to patients; pa-
tients asked to read
instruction
leaflet and indicate
understanding; in-
structions repeated
if poor understand-
ing indicated
Control: health staff
trained
to give oral instruc-
tions to patients; in-
structions repeated
if poor understand-
ing indicated
Interven-
tion: 1 dosage pre-
sentation, for adults
Control: none
Li 1998b 1. 3-day regimen of
chloroquine
2. 8-day regimen of
primaquine
Intervention
and control: tablets/
capsules
In-
tervention: 1 boxed
blister pack for each
drug; tablets/
capsules to be taken
each day together in
1 blister
Control: paper en-
velopes
Intervention: drug
name on blister
pack (back) and box
(front); dosage in-
structions and pre-
cautions on back
of box; instruction
leaflet inside box
Control: none
Interven-
tion and control: no
information
Interven-
tion: 1 dosage pre-
sentation, for adults
Control: none
Yeboah-Antwi 2001 3-day regimen of
chloroquine
Intervention and
control: tablets
Intervention:
hermetically sealed,
sectioned polythene
bags with daily dose
of tablets in each
section
Control: paper en-
velopes
Intervention: bag la-
belled with name of
drug; each section
labelled 1, 2, 3 (day
to be taken)
Control: none
Interven-
tion: prescribers and
dispensers trained in
prescribing and dis-
pensing drugs; told
to
use labelling when
instructing partici-
pants onhow to take
medication
Control:
same counselling as
intervention group
in terms of how
Interven-
tion: 3 dosage pre-
sentations available,
1 for each age group:
7 to 11 year; 12 to
15 years; and 16 and
above years
Control: no dosage
presentations avail-
able
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much drug to take,
but there were sig-
nificant differences
in all other aspects
of counselling;more
participants in the
intervention group
were told the names
of drugs, purpose of
drugs, how long to
take them, and some
possible side effects
Note: staff at
the control facilities
were more qualified
as dis-
pensers than those
at the intervention
facilities; all partic-
ipants in the inter-
vention group were
served by auxiliary
staff with no base-
line training; about
2/3 participants in
the control group
were served by a dis-
pensing assistant/at-
tendant with train-
ing in dispensing
Appendix 3. Risk of bias assessmenta
Trial name Allocation sequence
generation
Allocation concealment Blinding of outcome as-
sessor
Inclusionb
Ansah 2003 Inadequate Unclear Absent Adequate
Lauwo 2006 Unclear Unclear Absent Inadequate
Li 1998a Inadequate Unclear Absent Unclear
Li 1998b Inadequate Unclear Absent Unclear
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(Continued)
Yeboah-Antwi 2001c Adequate Unclear Absent Unclear
aSee the ’Assessment of risk of bias in included studies’ for methods and the ’Characteristics of included studies’ for the methods used
in each trial.
bInclusion of all randomized participants in the final analysis.
cTrialists did not take clustering into account in the analysis of this cluster-randomized controlled trial.
Appendix 4. Treatment adherence (level to dose ratio of drug marker; from Li 1998b)
Antimalarial drug Tablets and capsules
Blister packsa Paper envelopesa
Chloroquine Number of participants: 36
Median: 3.86
Range: 1.2 to 18.85
Number of participants: 23
Median: 3.46
Range: 1.99 to 30.9
Primaquine Number of participants: 31
Median: 7.25
Range: 2.29 to 19.99
Number of participants: 34
Median: 7.12
Range: 3.74 to 30.24
Appendix 5. Adverse events (from Yeboah-Antwi 2001a)
Adverse eventb Sectioned bagsc Paper envelopesd
Itching 12/167 16/152
Dizziness 6/167 5/152
“Other” 5/167 3/152
aCluster-randomized controlled trial.
bNumber of participants experiencing the event.
cSectioned polythene bags (tablets).
dTablets.
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WH A T ’ S N E W
Last assessed as up-to-date: 24 March 2009.
26 May 2009 New search has been performed One new trial included in the review. Inclusion criteria updated to exclude con-
trolled before and after studies. Treatment failure at day 14 removed from primary
outcome measures and made secondary. No change to conclusions.
H I S T O R Y
Protocol first published: Issue 1, 2004
Review first published: Issue 2, 2005
3 November 2008 Amended Converted to new review format with minor editing.
11 January 2005 Amended Issue 2, 2005 (Deviations from protocol)
(1) Title: changed from ’Pre-packaged drugs for treating malaria’ to ’Unit-dose packaged drugs for
treating malaria’ for a more specific definition of the intervention.
(2) Types of intervention: different drug formulations may now be used in the intervention and
control arms, as these may form useful comparisons, but we will not combine the data with data
from studies using the same formulation in intervention and control arms.
(3) Types of outcomes: treatment failure outcome measures altered to conform to new standards;
this involved removing “parasite failure rate” and replacing “early” and “late” treatment failure with
treatment failure on or by day 14/28.
(4) Methods of the review: inclusion of 80% of all randomized participants considered adequate,
rather than 90%, to take into account the difficulty in carrying out studies of this type of interven-
tion.
C O N T R I B U T I O N S O F A U T H O R S
Lois Orton extracted and analysed data and drafted the review. Guy Barnish extracted data and commented on the review.
D E C L A R A T I O N S O F I N T E R E S T
Guy Barnish was involved in one of the included trials, however he knows of no conflicts of interest. Lois Orton has no known conflicts
of interest.
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S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2005, Issue 2 (first review version): (1) Title: changed from ’Pre-packaged drugs for treating malaria’ to ’Unit-dose packaged drugs
for treating malaria’ for a more specific definition of the intervention. (2) Types of intervention: different drug formulations may now
be used in the intervention and control arms, as these may form useful comparisons, but we will not combine the data with data
from studies using the same formulation in intervention and control arms. (3) Types of outcomes: treatment failure outcome measures
altered to conform to new standards; this involved removing “parasite failure rate” and replacing “early” and “late” treatment failure
with treatment failure on or by day 14/28. (4) Methods of the review: inclusion of 80% of all randomized participants considered
adequate, rather than 90%, to take into account the difficulty in carrying out studies of this type of intervention.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimalarials [∗administration & dosage]; Drug Packaging [∗methods]; Malaria [∗drug therapy]; Patient Compliance; Randomized
Controlled Trials as Topic
MeSH check words
Humans
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